A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial

尼妥珠单抗 医学 放化疗 内科学 临床研究阶段 不利影响 危险系数 临床终点 癌症 肿瘤科 人口 胃肠病学 外科 置信区间 临床试验 表皮生长因子受体 环境卫生
作者
Gilberto de Castro,J. G. M. Segalla,Sérgio Jobim Azevedo,Carlos José Coelho de Andrade,D. Grabarz,Bruno de Araújo Lima França,Auro del Giglio,Nicolas Lazaretti,Maria Nunes Álvares,José Luiz Pedrini,Celio Kussumoto,João Nunes de Matos Neto,Nora Manoukian Forones,Hezio Jadir Fernandes Júnior,Giuliano Santos Borges,Gustavo Girotto,Ismael Dale Cotrim Guerreiro da Silva,Fauze Maluf‐Filho,Nils Gunnar Skare
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:88: 21-30 被引量:51
标识
DOI:10.1016/j.ejca.2017.10.005
摘要

Purpose Chemoradiotherapy is the standard treatment for patients with inoperable locally advanced oesophageal cancer. We sought to assess the safety and efficacy of chemoradiation combined with nimotuzumab, a humanised antibody directed against epidermal growth factor receptor (EGFR). Patients and methods Untreated patients with inoperable locally advanced oesophageal cancer and no distant metastases were randomised to chemoradiotherapy (cisplatin and fluorouracil combined with external beam radiation) alone or in combination with nimotuzumab. The primary end-point was the endoscopic complete response (eCR) rate, and secondary end-points comprised quality of life (QoL) and safety. The combined eCR and pathologic complete response (cEPCR) and overall survival (OS) were also evaluated. Results We enrolled 107 patients with a mean age of 59 years, and 93% had squamous cell carcinoma. Toxicity was manageable in both arms with no important differences in adverse events (AEs). We performed post-treatment endoscopies in 67 patients, including 60 who had a biopsy. In the intent-to-treat population, the eCR rates with and without nimotuzumab were 47.2% and 33.3% (P = 0.17), respectively, and the cEPCR rates were 62.3% and 37.0% (P = 0.02), respectively. With a median follow-up of 14.7 months, the hazard ratio (HR) for OS was 0.68 (95% confidence interval (CI): 0.44–1.07; P = 0.09) with a median OS of 15.9 months for the nimotuzumab arm and 11.5 months for the control arm. Regarding QoL, a significant difference was observed for the physical subscale score (P = 0.03) with lower values for the control arm. Conclusion Combined chemoradiotherapy plus nimotuzumab is safe for patients with locally advanced oesophageal cancer, it appears to increase the cEPCR rate, and without compromising QoL. Clinical trials Identification number: EF024-201; Trial registry: NCT01249352.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
雪花发布了新的文献求助10
1秒前
周全完成签到 ,获得积分10
5秒前
water应助科研通管家采纳,获得10
6秒前
Owen应助科研通管家采纳,获得10
6秒前
内向忆南完成签到,获得积分10
9秒前
翱翔者完成签到 ,获得积分10
12秒前
kryptonite完成签到 ,获得积分10
12秒前
月军完成签到,获得积分10
13秒前
欢呼寻冬完成签到 ,获得积分10
14秒前
西安浴日光能赵炜完成签到,获得积分10
15秒前
Joy完成签到 ,获得积分10
16秒前
Olsters完成签到 ,获得积分10
19秒前
老程完成签到,获得积分10
20秒前
zyb完成签到 ,获得积分10
23秒前
laber完成签到,获得积分0
23秒前
yue完成签到,获得积分10
23秒前
与共完成签到 ,获得积分10
26秒前
量子星尘发布了新的文献求助10
27秒前
gzf完成签到 ,获得积分10
28秒前
28秒前
D调的华丽完成签到,获得积分10
32秒前
xingxinghan完成签到 ,获得积分10
32秒前
ColinWine完成签到 ,获得积分10
35秒前
mix完成签到,获得积分10
35秒前
动听的谷秋完成签到 ,获得积分10
36秒前
刻苦努力的火龙果完成签到,获得积分10
37秒前
lling完成签到 ,获得积分10
40秒前
听寒完成签到,获得积分10
42秒前
珍珠火龙果完成签到 ,获得积分10
45秒前
似水流年完成签到 ,获得积分10
46秒前
sysi完成签到 ,获得积分10
1分钟前
绿波电龙完成签到,获得积分10
1分钟前
1分钟前
ZZzz完成签到 ,获得积分10
1分钟前
wujiwuhui发布了新的文献求助10
1分钟前
1分钟前
梦梦的小可爱完成签到 ,获得积分10
1分钟前
xinjie发布了新的文献求助10
1分钟前
1分钟前
蛋花肉圆汤完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022